Try our mobile app

Published: 2020-12-16 17:14:51 ET
<<<  go to VCYT company page
vcyt20200624_8k.htm
false 0001384101 0001384101 2020-12-16 2020-12-16
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): December 16, 2020
 
VERACYTE, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
001-36156
20-5455398
(State or other jurisdiction of incorporation)
Commission File Number
(IRS Employer Identification No.)
 
6000 Shoreline Court, Suite 300, South San Francisco, California
94080
(Address of principal executive offices)
(Zip Code)
 
Registrant’s telephone number, including area code: (650) 243-6300
 
N/A
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading Symbol(s)
  
Name of each exchange on which registered
Common Stock, par value, $0.001 per share
  
VCYT
  
The Nasdaq Stock Market LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
 
Item 8.01 Other Events.
 
On December 16, 2020, Veracyte, Inc. (the "Company") announced new preliminary performance data for its noninvasive nasal swab test for early lung cancer detection and its Percepta Genomic Atlas for informing treatment decisions at the time of diagnosis. The data were shared during the Company's Virtual Lung Cancer R&D Day, which was held December 16, 2020. A copy of the Company’s press release relating to this announcement is being furnished as Exhibit 99.1 to this Form 8-K.
 
Item 9.01 Financial Statements and Exhibits.
 
d) Exhibits
 
Exhibit No.
  
Description
     
 
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated:
December 16, 2020
    
       
   
VERACYTE, INC.
       
   
By:
/s/ Jim Erlinger
   
Name:
Jim Erlinger
   
Title:
Executive Vice President and General Counsel